scispace - formally typeset
Journal ArticleDOI

ACG Clinical Guideline: Management of Crohn’s Disease in Adults

Reads0
Chats0
TLDR
This guideline is intended to be flexible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are inflexible and rarely violated.
About
This article is published in The American Journal of Gastroenterology.The article was published on 2018-04-01. It has received 755 citations till now. The article focuses on the topics: Management of Crohn's disease & Disease.

read more

Citations
More filters
Journal ArticleDOI

ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment

Joana Torres, +46 more
TL;DR: The present article addresses surgical management, including preoperative aspects and drug management before surgery, and provides technical advice for a variety of common clinical situations.
Journal ArticleDOI

The microbiome and inflammatory bowel disease.

TL;DR: The role of the gut microbiome in patients with IBD is discussed and the possible benefits of microbiome-modulating interventions, such as probiotics, prebiotics, antibiotics, fecal microbiota transplantation, and gene manipulation are discussed.
References
More filters
Journal ArticleDOI

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

TL;DR: The advantages of the GRADE system are explored, which is increasingly being adopted by organisations worldwide and which is often praised for its high level of consistency.
Journal ArticleDOI

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

TL;DR: Patients with moderate-to-severe Crohn's disease who were treated with infliximab plus azathioprine or inflIXimab monotherapy were more likely to have a corticosteroid-free clinical remission than those receiving azATHioprine monotherapy.
Related Papers (5)